{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T18:35:53Z","timestamp":1778956553593,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T00:00:00Z","timestamp":1441238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00520-015-2924-1","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T02:04:51Z","timestamp":1441159491000},"page":"1365-1371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate"],"prefix":"10.1007","volume":"24","author":[{"given":"Helen","family":"Vol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Flank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara R.","family":"Lavoratore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyse","family":"Zelunka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lee Dupuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,3]]},"reference":[{"key":"2924_CR1","author":"J Liu","year":"2014","unstructured":"Liu J, Tan L, Zhang H, et al. (2014) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. European Journal of Cancer Care. doi: 10.1111\/ecc.12260","journal-title":"European Journal of Cancer Care"},{"key":"2924_CR2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"C Sun","year":"2005","unstructured":"Sun C, Bodurka D, Weaver C, et al. (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Supportive Care of Cancer 13:219\u2013227","journal-title":"Supportive Care of Cancer"},{"key":"2924_CR3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00520-009-0651-1","volume":"18","author":"LL Dupuis","year":"2010","unstructured":"Dupuis LL, Milne-Wren C, Cassidy M, et al. (2010) Symptom assessment in children receiving cancer therapy: the parents\u2019 perspective. Support Care Cancer 18:281\u2013299","journal-title":"Support Care Cancer"},{"key":"2924_CR4","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.ejca.2009.04.020","volume":"45","author":"PS Hinds","year":"2009","unstructured":"Hinds PS, Gattuso JS, Billups CA, et al. (2009) Aggressive treatment of non-metastatic osteosarcoma improves health-related quality of life in children and adolescents. Eur J Cancer 45:2007\u20132014","journal-title":"Eur J Cancer"},{"key":"2924_CR5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00148581-200305090-00003","volume":"5","author":"LL Dupuis","year":"2003","unstructured":"Dupuis LL, Nathan PC (2003) Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Pediatr Drugs 5:597\u2013613","journal-title":"Pediatr Drugs"},{"key":"2924_CR6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/PPO.0b013e31816a0f07","volume":"14","author":"L. Lohr","year":"2008","unstructured":"Lohr L (2008) Chemotherapy-induced nausea and vomiting. Cancer J 14:85\u201393","journal-title":"Cancer J"},{"key":"2924_CR7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejphar.2013.10.015","volume":"722","author":"D. Warr","year":"2014","unstructured":"Warr D (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192\u2013196","journal-title":"Eur J Pharmacol"},{"key":"2924_CR8","unstructured":"Guideline for classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. 2010. (Accessed November 11, 2012, at http:\/\/www.pogo.ca\/healthcare\/practiceguidelines\/ .)"},{"key":"2924_CR9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/pbc.23114","volume":"57","author":"L Dupuis","year":"2011","unstructured":"Dupuis L, Boodhan S, Sung L, et al. (2011) Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57:191\u2013198","journal-title":"Pediatr Blood Cancer"},{"key":"2924_CR10","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/cncr.21631","volume":"106","author":"MT Holdsworth","year":"2006","unstructured":"Holdsworth MT, Raisch DW, Frost J (2006) Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 106:931\u2013940","journal-title":"Cancer"},{"key":"2924_CR11","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1592\/phco.26.9.1221","volume":"26","author":"LL Dupuis","year":"2006","unstructured":"Dupuis LL, Taddio A, Kerr EN, Kelly A, MacKeigan L (2006) Development and validation of a pediatric nausea assessment tool (PeNAT) for use by children receiving antineoplastic agents. Pharmacotherapy 26:1221\u20131231","journal-title":"Pharmacotherapy"},{"key":"2924_CR12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s005200050157","volume":"6","author":"PJ Hesketh","year":"1998","unstructured":"Hesketh PJ, Gralla RJ, du Bois A, Tonato M (1998) Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Support Care Cancer 6:221\u2013227","journal-title":"Support Care Cancer"},{"key":"2924_CR13","unstructured":"Guideline for the prevention and treatment of anticipatory nausea and vomiting due to antineoplastic medication in pediatric cancer patients. 2013. at http:\/\/www.pogo.ca\/healthcare\/practiceguidelines\/ .)"},{"key":"2924_CR14","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud A, Hesketh P, et al. (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189\u20134198","journal-title":"J Clin Oncol"},{"key":"2924_CR15","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","volume":"24","author":"MG Kris","year":"2006","unstructured":"Kris MG, Hesketh PJ, Somerfield MR, et al. (2006) American Society of Clinical Oncology guidelines for antiemetics in oncology: update 2006. J Clin Oncol 24:2932\u20132947","journal-title":"J Clin Oncol"},{"key":"2924_CR16","doi-asserted-by":"crossref","unstructured":"Gilmore JW, Peacock NW, Gu A, et al. (2013) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. Journal of Oncology Practice","DOI":"10.1200\/JOP.2012.000816"},{"key":"2924_CR17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/pbc.24508","volume":"60","author":"LL Dupuis","year":"2013","unstructured":"Dupuis LL, Boodhan S, Holdsworth M, et al. (2013) Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 60:1073\u20131082","journal-title":"Pediatr Blood Cancer"},{"key":"2924_CR18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","volume":"73","author":"RM Navari","year":"2013","unstructured":"Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73:249\u2013262","journal-title":"Drugs"},{"key":"2924_CR19","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2000.18.19.3409","volume":"18","author":"J Ioannidis","year":"2000","unstructured":"Ioannidis J, Hesketh P, Lau J (2000) Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 18:3409\u20133422","journal-title":"J Clin Oncol"},{"key":"2924_CR20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188\u2013195","journal-title":"J Support Oncol"},{"key":"2924_CR21","doi-asserted-by":"crossref","unstructured":"Shumway N, Terrazzino S, Jones C. (2009) A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. Journal of Clinical Oncology 27:516s. [abstract].","DOI":"10.1200\/jco.2009.27.15_suppl.9633"},{"key":"2924_CR22","unstructured":"MASCC\/ESMO Antiemetic Guideline 2013. 2013. (Accessed May 27, 2013, at http:\/\/www.mascc.org\/assets\/documents\/mascc_guidelines_english_2013.pdf .)"},{"key":"2924_CR23","volume-title":"Evaluating the use of palonosetron in pediatric patients for the prevention of chemotherapy induced nausea and vomiting (CINV)","author":"N Adel","year":"2005","unstructured":"Adel N, Lucarelli C, Khan A, Kellick M (2005) Evaluating the use of palonosetron in pediatric patients for the prevention of chemotherapy induced nausea and vomiting (CINV). Mid-year Clinical Meeting American Society of Health-System Pharmacists, Las Vegas"},{"key":"2924_CR24","first-page":"842","volume":"57","author":"A Chandra","year":"2011","unstructured":"Chandra A, Khetan V (2011) Children on chemotherapy treated with palonosetron, aprepitant and dexamethasone as a antiemetic, a study from India. [Abstract]. Pediatr Blood Cancer 57:842","journal-title":"Pediatr Blood Cancer"},{"issue":"June 20 suppl","key":"2924_CR25","doi-asserted-by":"crossref","first-page":"9570","DOI":"10.1200\/jco.2007.25.18_suppl.9570","volume":"25","author":"R Kadota","year":"2007","unstructured":"Kadota R, Shen V, Messinger Y (2007) Safety, pharmacokinetics, and efficacy of palonosetron in pediatric patients: a multicenter, stratified, double-blind, phase 3, randomized study. Journal of Clinical Oncology 25(June 20 suppl):9570[abstract]","journal-title":"Journal of Clinical Oncology"},{"key":"2924_CR26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/pbc.24068","volume":"59","author":"S Nadaraja","year":"2012","unstructured":"Nadaraja S, Mamoudou A, Thomassen H, Wehner P, Rosthoej S, Schroeder H (2012) Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate. Pediatr Blood Cancer 59:870\u2013873","journal-title":"Pediatr Blood Cancer"},{"key":"2924_CR27","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bmt.2010.23","volume":"45","author":"M Ripaldi","year":"2010","unstructured":"Ripaldi M, Parasole R, De Simone G, et al. (2010) Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety. [letter]. Bone Marrow Transplant 45:1663\u20131664","journal-title":"Bone Marrow Transplant"},{"key":"2924_CR28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.arcmed.2008.04.007","volume":"39","author":"A Sepulveda-Vildosola","year":"2008","unstructured":"Sepulveda-Vildosola A, Betanzos-Cabrera Y, Lastiri G, et al. (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Archives Med Research 39:601\u2013606","journal-title":"Archives Med Research"},{"key":"2924_CR29","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/pbc.24296","volume":"60","author":"G Varasso","year":"2013","unstructured":"Varasso G, De Grazia A, Mollace M, Megaro G, Paiano M, Suraci S (2013) Antiemetic efficacy of palonosetron in children receiving moderately emetogenic chemotherapy: preliminary results, [Abstract]. Pediatr Blood Cancer 60:S3","journal-title":"Pediatr Blood Cancer"},{"key":"2924_CR30","doi-asserted-by":"crossref","unstructured":"Kovacs G, Wachtel A, Basharova E, Spinelli T, Nicolas P, Kabickova E. efficacy\/safety of palonosetron vs ondansetron in preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric patients receiving moderately or highly emetogenic chemotherapy (MEC\/HEC). Annals of Oncology 2014;25 (suppl 4).[abstract].","DOI":"10.1093\/annonc\/mdu356.1"},{"issue":"S2","key":"2924_CR31","first-page":"S108","volume":"61","author":"G Kovacs","year":"2014","unstructured":"Kovacs G, Wachtel A, Basharova E, Spinelli T, Nicolas P, Kabickova E (2014) Analysis of palonosetron vs ondansetron in preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric patients receiving moderately or highly emetogenic chemotherapy (MEC\/HEC). [Abstract]. Pediatr Blood Cancer 61(S2):S108","journal-title":"Pediatr Blood Cancer"},{"key":"2924_CR32","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/pbc.25108","volume":"61","author":"J Freedman","year":"2014","unstructured":"Freedman J, Faerber J, Kang T, et al. (2014) Predictors of antiemetic alteration in pediatric acute myeloid leukemia. Pediatric Blood and Cancer 61:1798\u20131805","journal-title":"Pediatric Blood and Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2924-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-2924-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2924-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T21:32:31Z","timestamp":1599514351000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-2924-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["2924"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-2924-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,3]]}}}